The significant improvement of survival times and pathological parameters by bioartificial liver with recombinant HepG2 in porcine liver failure model

Cell Transplantation

Volumn 15, Issue 10, 2006, Pages 873-880

  Enosawa, Shin ^a   Miyashita, Tomoyuki ^a   Saito, Tomohiro ^a   Omasa, Takeshi ^b   Matsumura, Toshiharu ^c  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Roman Industries Co Ltd   (Japan)

Author keywords

Bioartificial liver (BAL); HepG2; Ischemic liver failure; Porcine hepatocytes

Indexed keywords

AMMONIA; GLUTAMATE AMMONIA LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BIOARTIFICIAL LIVER; CELL COUNT; CELL STRAIN HEPG2; CELL SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; GENETIC RECOMBINATION; GENETIC TRANSFECTION; GS GENE; HEPATOBLASTOMA; HUMAN; HUMAN CELL; INTRACRANIAL PRESSURE; LIVER CELL CULTURE; LIVER FAILURE; LIVER ISCHEMIA; NONHUMAN; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; REACTOR MONITORING; SWINE; TRANSGENE;

ANIMALS; BIOREACTORS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL TRANSPLANTATION; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; GLUTAMATE-AMMONIA LIGASE; HUMANS; LIVER FAILURE; LIVER, ARTIFICIAL; MALE; MODELS, BIOLOGICAL; SURVIVAL RATE; SWINE; TRANSFECTION;

ANIMALIA; SUIDAE; SUS;

EID: 33846649619     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000006783981350     Document Type: Conference Paper

References (24)

1. Brandt, J. T. Hemostasis. In: Howanitz, J. H.; Howanitz, P. J., eds. Laboratory medicine. New York: Churchhill Livingstone Inc.; 1991:499-552.
2. Catapano, G.; Euler, M.; Gaylor, J. D. S.; Gerlach, J. Characterization of the distribution of matter in hybrid liver support devices where cells are cultured in a 3-D membrane network or on flat substrata. Int. J. Artif. Organs 24(2):102-109; 2001.
3. Chamuleau, R. A. F. M. Hepatocyte transplantation for acute hepatic failure. In: Mito, M.; Sawa, M., eds. Hepatocyte transplantation. Basel: Karger Landes Systems; 1997:157-167.
4. Detry, O.; Arkadopoulos, N.; Ting, P.; Kahaku, E.; Watanabe, F. D.; Rozga, J.; Demetriou, A. A. Clinical use of a bioartificial liver in the treatment of acetaminophen-induced fulminant hepatic failure. Am. Surg. 65(10):934-938; 1999.
5. Ellis, A. J.; Hughes, R. D.; Wendon, J. A.; Dunne, J.; Langley, P. G.; Kelly, J. H.; Gislason, G. T.; Sussman, N. L.; Williams, R. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 24(6):1446-1451; 1996.
6. Enosawa, S.; Suzuki, S.; Kakefuda, T.; Amemiya, H. Examination of 7-ethoxycoumarin deethylation and ammonia removal activities in 31 hepatocyte cell lines. Cell Transplant. 5(Suppl. 1):39-41; 1996
7. Enosawa, S.; Miyashita, T.; Suzuki, S.; Li, X. K.; Tsunoda, M.; Amemiya, H.; Yamanaka, M.; Hiramatsu, S.; Tanimura, N.; Omasa, T.; Suga, K.; Matsumura, T. Long-term culture of glutamine synthetase-transfected HepG2 cells in circulatory flow bioreactor for development for a bioartificial liver. Cell Transplant. 9(5):711-715; 2000.
8. Enosawa, S.; Miyashita, T.; Fujita, Y.; Suzuki, S.; Amemiya, H.; Omasa, T.; Hiramatsu, S.; Suga, K.; Matsumura, T. In vivo estimation of bioartificial liver with recombinant HepG2 cells using pigs with ischemic liver failure. Cell Transplant. 10(4-5):429-433; 2001.
9. Enosawa, S.; Miyashita, T.; Li, X. K.; Suzuki, S.; Amemiya, H.; Omasa, T.; Suga, K.; Matsumura, T. Bioreactor with glutamine synthetase-transfected recombinant HepG2 cells exhibits the ammonia removal activity needless of adding cofactors and substrates: Advantage of cellular bioreactor that surpass enzyme-immobilized beads?. J. Artif. Organs 4:348-352; 2001.
10. Enosawa, S.; Mukaiyama, T.; Miyashita, T.; Li, X. K.; Suzuki, S.; Amemiya, H.; Matsumura, T.; Omasa, T.; Suga, K. Application of circulatory flow bioreactor for long-term and large-scale culture of glutamine synthetase transfected CHO cells and its ammonia removal activity with an aim of development for bioartificial liver assist system. J. Artif. Organs 4:61-66; 2001.
11. Enosawa, S.; Miyashita, T.; Endo, M.; Suzuki, S.; Amemiya, H.; Matsumura, T. Off-line bioartificial liver: A novel concept of treatment and its potency of liver regeneration. Transplant. Proc. 34(7):2711-2713; 2002.
12. Hirasawa, H.; Sugai, T.; Ohtake, Y.; Oda, S.; Matsuda, K.; Kitamura, N. Blood purification for prevention and treatment of multiple organ failure. World J. Surg. 20(4):482-486; 1996.
13. Kubota, T.; Takabe, K.; Yang, M.; Sekido, H.; Endo, I.; Ichikawa, Y.; Togo, S.; Shimada, H. Minimum sizes for remnant and transplanted livers in rats. J. Hep. Bil. Pancr. Surg. 4:398-404; 1997.
14. Makowka, L.; Falk, R. E.; Rotstein, L. E.; Falk, J. A.; Nossal, N.; Langer, B.; Blendis, L. M.; Phillips, M. J. Cellular transplantation in the treatment of experimental hepatic failure. Science 210(4472):901-903; 1980.
15. Matsumura, K. N.; Guevara, G. R.; Huston, H.; Hamilton, W. L.; Rikimaru, M.; Yamasaki, G.; Matsumura, M. S. Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery 101(1):99-103; 1987.
16. Mazariegos, G. V.; Kramer, D. J.; Lopez, R. C.; Shakil, A. O.; Rosenbloom, A. J.; DeVera, M.; Giraldo, M.; Grogan, T. A.; Zhu, Y.; Fulmer, M. L.; Amiot, B. P.; Patzer, J. F. Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients. ASAIO J. 47(5):471-475; 2001.
17. Miyashita, T.; Enosawa, S.; Suzuki, S.; Tamura, A.; Tanaka, H.; Amemiya, H.; Matsumura, T.; Omasa, T.; Suga, K.; Aoki, T.; Koyanagi, Y. Development of a bioartificial liver with glutamine synthetase-transduced recombinant human hepatoblastoma cell line, HepG2. Transplant. Proc. 32(7):2355-2358; 2000.
18. Miyashita, T.; Enosawa, S.; Tanaka, H.; Tamura, A.; Amemiya, H.; Aoki, T.; Koyanagi, Y.; Suzuki, S. Standardization of ischemic hepatic failure in pigs as a model for bioartificial liver assessment. Surg. Today 33(10):743-750; 2003.
19. Omasa, T.; Yamanaka, M.; Tanimura, N.; Katakura, Y.; Kishimoto, M.; Suga, K.; Enosawa, S. Expression and amplification of glutamine synthetase gene endows HepG2 cells with ammonia-metabolizing activity for bioartificial liver support system. Enzyme Microbial. Technol. 35(6-7):519-524; 2004.
20. Paradis, K.; Langford, G.; Long, Z.; Heneine, W.; Sandstrom, P.; Switzer, W. M.; Chapman, L. E.; Lockey, C.; Onions, D.; Otto, E. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science 285(5431):1236-1241; 1999.
21. Patience, C.; Takeuchi, Y.; Weiss, R. A. Zoonosis in xenotransplantation. Curr. Opin. Immunol. 10(5):539-542; 1998.
22. Sussman, N. L.; Chong, M. G.; Koussayer, T.; He, D. E.; Shang, T. A.; Whisennand, H. H.; Kelly, J. H. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 16(1):60-65; 1992.
23. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health. Guide for the care and use of laboratory animals. NIH Publication No.85-23, 1985.
24. Van de Kerkhove, M. P.; Di Florio, E.; Scuderi, V.; Mancini, A.; Belli, A.; Bracco, A.; Scala, D.; Scala, S.; Zeuli, L.; Di Nicuolo, G.; Amoroso, P.; Calise, F.; Chamuleau, R. A. Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver. Cell Transplant. 12(6):563-568; 2003.